Antibodies to combat viral infections: development strategies and progress
G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022 - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
insights on current FDA-approved monoclonal antibodies against Ebola virus infection
O Tshiani Mbaya, P Mukumbayi… - Frontiers in immunology, 2021 - frontiersin.org
The unprecedented 2013-2016 West Africa Ebola outbreak accelerated several medical
countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational …
countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational …
Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone
Summary The 2013–2015 Ebola virus disease (EVD) epidemic is caused by the Makona
variant of Ebola virus (EBOV). Early in the epidemic, genome sequencing provided insights …
variant of Ebola virus (EBOV). Early in the epidemic, genome sequencing provided insights …
[HTML][HTML] Human adaptation of Ebola virus during the West African outbreak
The 2013–2016 outbreak of Ebola virus (EBOV) in West Africa was the largest recorded. It
began following the cross-species transmission of EBOV from an animal reservoir, most …
began following the cross-species transmission of EBOV from an animal reservoir, most …
Longitudinal analysis of the human B cell response to Ebola virus infection
Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B
cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection …
cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection …
Structural and molecular basis for Ebola virus neutralization by protective human antibodies
Ebola virus causes hemorrhagic fever with a high case fatality rate for which there is no
approved therapy. Two human monoclonal antibodies, mAb100 and mAb114, in …
approved therapy. Two human monoclonal antibodies, mAb100 and mAb114, in …
Structures of protective antibodies reveal sites of vulnerability on Ebola virus
CD Murin, ML Fusco, ZA Bornholdt… - Proceedings of the …, 2014 - National Acad Sciences
Ebola virus (EBOV) and related filoviruses cause severe hemorrhagic fever, with up to 90%
lethality, and no treatments are approved for human use. Multiple recent outbreaks of EBOV …
lethality, and no treatments are approved for human use. Multiple recent outbreaks of EBOV …
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus
GS Mohan, W Li, L Ye, RW Compans, C Yang - PLoS pathogens, 2012 - journals.plos.org
In addition to its surface glycoprotein (GP1, 2), Ebola virus (EBOV) directs the production of
large quantities of a truncated glycoprotein isoform (sGP) that is secreted into the …
large quantities of a truncated glycoprotein isoform (sGP) that is secreted into the …
African swine fever virus uses macropinocytosis to enter host cells
EG Sánchez, A Quintas, D Pérez-Núñez… - PLoS …, 2012 - journals.plos.org
African swine fever (ASF) is caused by a large and highly pathogenic DNA virus, African
swine fever virus (ASFV), which provokes severe economic losses and expansion threats …
swine fever virus (ASFV), which provokes severe economic losses and expansion threats …
Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects
Although substantial progress has been made with Ebola virus (EBOV) vaccine measures,
the immune correlates of vaccine-mediated protection remain uncertain. Here, five mucosal …
the immune correlates of vaccine-mediated protection remain uncertain. Here, five mucosal …